Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (800)	1/24/1998 6:31:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

They are talking about delivery of small molecules for multiple sclerosis, not asthma. In other words they have a small molecular alternative for their interferon product, Avonex, which is a protein and must be injected. It's quite a stretch to think that this has anything whatsoever to do with their anti-asthma product. HE, I noticed that you're the person who started the Biogen thread. I hope you hedged your bets by buying some Inflazyme. Also, the Biogen conference call of January 15, which was generously posted by their investor relations dept. on Jan. 23, makes me think that they would be more than happy to find and post answers to any questions on this reputed anti-asthma drug, their VLA-4 inhibitor, that I might ask on their thread. What do you think?